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cardiac four-dimensional CT (4D-CT) synchronized to the 
electrocardiogram were obtained in treatment position, using a 
prospective sequential acquisition method including the extreme 
phases of systole and diastole. On a MimVista® image 
registration workstation, dose distributions were transferred to 
the cardiac 4D-CT. The left coronary artery, left ventricle and 
heart were contoured on both phases of the cardiac cycle. The 
maximum and minimum doses to the left coronary, left ventricle 
and heart were compared using a bilateral paired Student T test.  
Results: Preliminary data from the first eight patients enrolled 
are presented. Median age was 60 years (56-71) and median 
planned dose to the left breast was 42.56 Gy (42.56-50) in 16 
fractions (16-20). For the left coronary artery, mean dose, V5 
and V20 in systole versus diastole were 6.1 Gy versus 7.9 Gy (p = 
0.02), 37% versus 48% (p = 0.02) and 10% versus 16% (p = 0.04), 
respectively. For the left ventricle, mean dose, V5 and V20 in 
systole versus diastole were 1.3 Gy versus 1.6 Gy (p = 0.005), 6% 
versus 9% (p = 0.03) and 1% versus 2% (p > 0.1), respectively. For 
the whole heart, mean dose, V5 and V20 in systole versus diastole 
were 0.9 Gy versus 1.3 Gy (p = 0.005), 21 cc versus 32 cc (p = 
0.07) and 4 cc versus 5 cc (p > 0.1), respectively. 
Conclusions: Beyond DIBH, systolic irradiation would be 
associated with a further reduction in V5, V20 and mean dose to 
the left coronary artery, as well as a reduction in V5 and mean 
dose to the left ventricle and heart as a whole. The potential 
clinical impact of this reduction as well as the feasibility of 
cardiac gated irradiation are to be further investigated. 
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Purpose: Non-melanoma skin cancers occurring in areas with 
irregular contours like the ear pose challenges in effectively 
delivering a therapeutic radiation dose using electrons. As 
electrons deliver dose at a depth, a tissue equivalent material 
called bolus must be placed on the skin so that therapeutic dose 
is delivered to the tumour. Commercially available bolus 
materials lack the ability to conform to a patient’s specific 
anatomy in areas with irregular contours. Such shortcomings can 
create air cavities between the tumour and bolus, and ultimately 
lead to treatment inaccuracy. A custom bolus can be made from 
wax, but this also has shortcomings. It is labour intensive and 
challenging to create a wax bolus with uniform specified 
thickness and minimal air gaps. As an alternative, we have 
developed a technique of generating soft silicone bolus, which 
conforms to irregular anatomy, using an optical scanner and rigid 
material 3D printer. 
Methods and Materials: Volunteer specific anatomy of the ear 
was acquired using a consumer-grade optical scanner (3D 
Systems, Sense). A three-dimensional model of each volunteer 
was exported to a mesh editing software (Autodesk, MeshMixer 
v2.9) where replica of the ear anatomy was designed. This 
replica was exported as an STL file to software controlling the 
printer (Repetier-Host), converted to gcode (Slic3r) and printed 
on a consumer-Grade 3D printer (MakerGear, M2). This replica 
served as a rigid mould for silicone rubber. The result was a soft 
bolus with one side flat and the other side perfectly fitting the 
ear. 
Results: The soft silicone bolus created by this technique 
perfectly fit the anatomy, was of desired thickness, comfortable 
to put on with no sharp edges. There were no air gaps visible. No 
air bubbles were found using x-ray imaging. Dosimetric studies 
were done on the silicone rubber and it was found acceptable to 
be used as a bolus material. 
Conclusions: Using an optical scanner and 3D printer enables us 
to create a soft, flexible silicone conformal bolus which is cost 
effective. Silicone bolus accurately fits with no air gaps and is 
better for irregular contours than a commercial or wax bolus. It 
is also better than a hard plastic 3D printed bolus for areas where 
a rigid bolus is difficult to use or causes patient discomfort. This 
approach does not require intensive training and enhances the 
patient experience as they can have an optical scan on the day 
of clinical appointment and directly come on the day of 
treatment. It also has potential to save treatment machine time 
because the setup time is anticipated to be reduced as the 
complexity of set up is greatly decreased.  
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Purpose: To determine the rates of urinary intervention for 
patients with low- and low-tier intermediate-risk prostate cancer 
treated with intraoperatively planned low dose rate prostate 
brachytherapy. 
Methods and Materials: From 2003-2012, 723 consecutive 
patients were treated with intraoperatively planned LDR 
prostate brachytherapy without external beam radiotherapy at 
our centre. Dosimetric planning targets were uniform with a goal 
of D90 prostate > 180 Gy, V150 > 74%, V200 > 37%, V140 urethra 
< 24% and V150 urethra < 3%. Patients were followed according 
to a protocol every 6 months for the first three years then 
annually. For each patient, all data were entered into a central 
database prospectively and retrospectively verified by reviewing 
a centralized electronic health record that comprehensively 
captures all interventions performed and visitations to any 
medical centre in the province of Alberta, Canada. Urinary 
interventions included cystoscopy, transurethral resection of the 
prostate, urethral dilatation or catheterization for urinary 
retention or hematuria attributable to brachytherapy. These 
patients were then isolated and compared with the remaining 
control cohort using tests of proportions and multivariate 
analysis as appropriate. 
Results: Median follow up was 7.1 years (range: 2.5 - 12.5). 
Intervention for RTOG Grade 3 toxicity was encountered in 51 
patients (7%). Cystoscopy was done in 31 patients (4.3%) for RT 
related hematuria or obstruction. TURP was performed in 14 
patients (1.9%) with a median time from implant of 20.4 months 
(range, 3-86) and dilatation for RT toxicity in six patients (0.8%) 
with a median time of 29 months (range, 20-85). Median pre-
implant volume was 37.1 cc (20.2 - 53.0) in patients having 
intervention for Grade 3 toxicity and 33.7 cc (13.2 - 66.9) in 
those without [p < 0.05]. Time from biopsy to implant, pre-
treatment AUA symptom score, PSA, clinical stage, use of 
hormones, and urethral dosimetry did not predict for urinary 
intervention in our analysis. 
Conclusions: Urinary intervention rates following 
intraoperatively planned LDR prostate brachytherapy are low 
overall at 7%. The strength of our study is the ability to review 
all hospital records in our health region to completely capture 
any urinary intervention due to an integrated electronic health 
records system. 
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Purpose: A 2011 survey on the practice of intensity-modulated 
radiotherapy (IMRT) in the treatment of vulvar carcinoma 
originally highlighted areas of controversy and subsequently lead 
to the establishment of consensus recommendations for 
contouring and treatment in vulvar carcinoma. The present study 
aims to outline changes in practice over the last five years. 
Methods and Materials: Radiation oncologists with an expertise 
in gynaecological malignancies from a multi-national consortium 
(North America, Australia and Europe) were asked to complete a 
web based survey in 2011, then in 2016. Questions covered a 
wide range of issues in regards to staging, planning and IMRT 
treatment of vulvar cancer. Pearson’s chi-squared test was used 
to compare the two surveys. 
Results: Thirty-five radiation oncologists completed the survey 
in 2011, 24 in 2016. Half of the respondents were from the USA. 
An increase in the use of IMRT was reported. In 2011, 29% have 
never used IMRT in the management of vulvar cancer, compared 
to 4% in 2016, and 23% have treated more than 10 patients with 
IMRT in 2011, compared to 75% in 2016 (p = 0.006). PET-CT was 
used for staging by 69% of respondents in 2011 as compared to 
88% in 2016 (p = 0.09). There was also an increase in the use of 
MRI for planning purposes (p = 0.018) and more physicians now 
report replanning during the course of treatment (74% versus 
25%; p = 0.001). More respondents now use a higher total dose (≥ 
66 Gy) to the primary lesion (55% versus 41%; p = 0.312) although 
it did not reach statistical significance. There remains 
controversy on the total dose to deliver to involved lymph nodes. 
Similarly, there remains considerable variation in clinical target 
volume (CTV) definitions for different clinical scenarios as well 
as dose constraints for organs at risk (OAR). There is a trend of 
an increasing bone marrow contouring by radiation oncologists 
(47% versus 29%; p = 0.19), but there is still considerable 
discrepancy in the pelvic bones selected to represent ‘bone 
marrow’. Weekly cisplatin at 40 mg/m2 remains the most 
commonly used concurrent chemotherapy regimen. 
Conclusions: The use of IMRT for vulvar cancer has increased 
over the past five years. CTV definition and OAR dose constraints 
remain the biggest areas of controversy, highlighting the need 
for new consensus recommendations. 
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Purpose: Patients with left-sided breast cancer receiving 
radiotherapy (RT) are at increased risk of cardiac toxicity. 
Anatomic features that predict which breast patients would 
benefit from BH-RT for cardiac-sparing have been proposed. The 
purpose of this study is to evaluate the performance of a new 
metric in comparison to existing predictors in determining the 
need for BH-RT. 
Methods and Materials: In this single institution study, 50 
randomly selected left-breast cancer patients treated with BH-
RT were evaluated. Free-breathing and breath-hold images are 
both acquired during planning and the former set were used in 
this analysis. Target volumes and organs at risk were contoured 
using RTOG and consensus-based atlases. Using a cut-off of > 10 
cc V50% or mean heart dose (MHD) ≥1.7 Gy as selection criteria 
for BH-RT, a study by Lee et al. previously described the 
parasagittal heart contact with the chest wall length 
(HeartContact) as the most accurate predictor of benefiting from 
BH-RT use. We evaluated the performance of HeartContact 
versus two new candidate variables, measured as the lateral 
length between the left sternal edge to the beginning of lung 
parenchyma at the 1) fourth (Arch4) and 2) fifth costal arch 
(Arch5) levels. These three independent variables were 
compared with mean heart dose (MHD), V50% heart volume and 
left anterior descending coronary (LAD) max dose. Recursive 
partioning analysis (RPA) was performed to define optimal cut-
points for independent variables. Sensitivity and specificity were 
calculated based on these parameters. Univariable regression 
analysis was used to identify significant predictors of breath hold 
end points. Statistical analyses were performed using SAS (v.9.4) 
with two-sided statistical testing at the 0.05 significance level. 
Results: The median patient age was 53 years and all underwent 
breast-conserving surgery. The MHD was 2.3 Gy (± 0.8) and mean 
V50% was 10.4 cc (± 9.7). RPA determined 73mm as the optimal 
cut-off for HeartContact, 13 mm for Arch4 and 60 mm for Arch5, 
respectively. When considering MHD ≥ 1.7 Gy to predict for BH-
RT, HeartContact sensitivity and specificity were 77% and 90%; 
with Arch4 yielding 80% and 90%, respectively. In the case of 
V50% ≥ 10 cc to predict for BH-RT, HeartContact sensitivity and 
specificity were 87% and 55%; Arch4 yielded values of 100% and 
63% respectively. Arch4 was more sensitive and specific in 
predicting BH-RT than Arch5. On univariable linear regression 
analysis, Heartcontact and Arch4 were found to be statistical 
significant predictors of MHD, V50% and LAD Max dose (p < 0.05). 
Receiver operating curves demonstrated that Arch4 was the most 
accurate predictor of high cardiac dose (MHD ≥ 1.7 Gy and V50% 
≥ 10 mL). 
Conclusions: Our proposed variable, Arch4 holds promise as a 
practical and accurate predictor of high heart dose and the need 
for BH-RT for left-sided breast cancer patients. An external 
validation study is planned to confirm the diagnostic 
performance of our novel variable. 
 
78 CARO FELLOWSHIP 
SERUM EXOSOMAL MICRORNAS (MIRNAS) AS NON-INVASIVE 
BIOMARKERS TO GUIDE POST-OPERATIVE RADIOTHERAPY IN 
PROSTATE CANCER (PCA) PATIENTS TREATED WITH RADICAL 
PROSTATECTOMY (RP)  
Alireza Fotouhi Ghiam1, Danny Vesprini1, Samira Taeb1, Sahar 
Jahangiri1, Xiaoyong Huang1, Jessica Ray1, Christianne Hoey1, 
Andrew Loblaw1, Emmanouil Fokas2, Stanley K. Liu1 
1University of Toronto, Toronto, ON 
2University of Oxford, Oxford, Oxford, United Kingdom 
 
Purpose: Despite possessing similar clinicopathological features, 
some PCa patients treated with RP are at high-risk of developing 
local and/or distant recurrence and dying of their cancer, 
whereas many others will have clinically insignificant disease and 
will not benefit from post-operative radiotherapy. A minimally 
invasive diagnostic assay is required to stratify these patients, 
monitor disease progression and response to treatment, 
ultimately improving patient care. Extracellular miRNAs 
embedded in circulating exosomes have sparked much interest 
as potential non-invasive biomarkers for PCa.  
Methods and Materials: Patients who had RP and were referred 
for post-operative radiotherapy were prospectively recruited 
and patient, tumour and treatment factors were abstracted and 
analyzed. Serum exosomes were isolated for extraction of 
miRNAs, and comparative profiling of miRNAs was performed 
